Blood flow dynamics during local photoreaction in a head and neck tumor model by Daniel J. Rohrbach et al.
ORIGINAL RESEARCH
published: 17 March 2015
doi: 10.3389/fphy.2015.00013
Frontiers in Physics | www.frontiersin.org 1 March 2015 | Volume 3 | Article 13
Edited by:
Zhen Cheng,
Stanford University, USA
Reviewed by:
Edite Figueiras,
Tampere University of Technology,
Finland
Jan Sedlacik,
University Medical Center
Hamburg-Eppendorf, Germany
*Correspondence:
Ulas Sunar,
Department of Biomedical
Engineering, University at Buffalo,
Buffalo, NY 14260, USA
ulassuna@buffalo.edu
Specialty section:
This article was submitted to
Biomedical Physics, a section of the
journal Frontiers in Physics
Received: 16 December 2014
Accepted: 26 February 2015
Published: 17 March 2015
Citation:
Rohrbach DJ, Tracy EC, Walker J,
Baumann H and Sunar U (2015)
Blood flow dynamics during local
photoreaction in a head and neck
tumor model. Front. Phys. 3:13.
doi: 10.3389/fphy.2015.00013
Blood flow dynamics during local
photoreaction in a head and neck
tumor model
Daniel J. Rohrbach 1, Erin C. Tracy 2, Jessica Walker 1, Heinz Baumann 2 and Ulas Sunar 1, 3*
1Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, USA, 2Department of Molecular and Cellular
Biology, Roswell Park Cancer Institute, Buffalo, NY, USA, 3Department of Biomedical Engineering, University at Buffalo,
Buffalo, NY, USA
We have applied continuous blood flow dynamics, quantified with diffuse correlation
spectroscopy (DCS), in investigating photodynamic therapy (PDT) induced local
photoreaction in a head and neck tumor model. Photoclor (0.47µmol/kg) was
intravenously administered 24 h before PDT. Two types of fluence rates were
implemented: Low fluence rate (14mW/cm2) and high fluence rate (75mW/cm2). The
total delivered fluence was 100 J/cm2 for both types. We observed that PDT induced
substantial vascular shut down in both types. While the shutdown was persistent
in tumors exposed to low fluence rate PDT, the shutdown was transient in tumors
exposed to high fluence PDT. Loss of microvascular structures was confirmed by the
microscopic analyses of tumor section following immunostaining for CD31. Blood flow
dynamics related metrics were also strongly correlated with crosslinking of STAT3, a
molecular marker of photoreaction. STAT3 analysis indicated that low fluence rate yields
a substantially higher photoreaction, and thus, a more effective PDT. Our results indicate
that non-invasive blood flow measurements can monitor the efficacy of PDT in real-time
and potentially provide a feedback for its optimization.
Keywords: blood flow, photodynamic therapy, vascular response, diffuse correlation spectroscopy, STAT3
crosslinking, biomarker, head and neck
Introduction
Head and neck tumors in the oral cavity are the sixth most common cancer in the world
[1]. With its increasing rate of incidence, a significant number of patients are diagnosed with
already well-defined tumors that require effective treatments. Conventional treatment options are
surgery, chemo, and/or radiation therapies. Surgery can result in functional losses of speech and
swallowing. Moreover, relapse following surgery has been reported as high as ∼30% [2]. Sim-
ilarly, chemotherapy showed high relapse rates and toxicities. Radiation therapy has improved
success rates, but the risk of acute and long-term injury to normal tissue (e.g., fibrotic com-
plications) can severely decrease quality of life. Any alternative therapy must balance thera-
peutic effectiveness with treatment toxicity. Such an alternative is provided by photodynamic
therapy (PDT), which relies on the optimal application of a tumor-localized photosensitizing
drug, oxygen, and light. PDT is a local therapy with superior healing without cumulative side
effects, and can be repeated several times [3]. It is particularly well suited for treatment of head
and neck cancers with multiple tumor foci or widespread diseases (e.g., leukoplakia or invasive
carcinoma in the oral cavity) [4]. However, PDT responses can vary from∼90 to∼45% depending
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on site, tumor stage and treatment protocols, which has ham-
pered wider clinical use [5–8].
For effective PDT, an optimal amount of photosensitizer (PS),
oxygen and light are required. The wavelength of treatment light
is chosen based on the absorption spectrum of the PS as well
as the necessary penetration depth of the light. The destruction
of cancer tissue by PDT can be due to direct killing of tumor
cells through generation of reactive oxygen species (ROS) [9], or
indirectly by reducing the blood supply through vascular damage
[10] or post-PDT activation of an antitumor immune response
[11]. The anti-vascular effects of PDT are particularly important
in determining the progression of the photoreaction and treat-
ment outcome. Areas with poor vasculature and low blood flow
are prone to have low uptake of intravenously administered pho-
tosensitizers and low oxygenation than regions with higher blood
flow [12]. This can affect PDT response significantly: hypoxic
regions have less oxygen available for photoreaction, leading to
poor PDT response [13], and high blood volume in some regions
can lead to significant attenuation of treatment light, limiting the
penetration depth and decreasing the zone of necrosis [14–16],
which ultimately can lead to sub-optimal treatment. In addition,
during the dynamic process of PDT, oxygen is consumed and,
depending on the choice of photosensitizer and light delivery,
blood vessels may be destroyed [17, 18]. This prevents supply of
nutrients and oxygen to the tumor after treatment, and leads to
effective destruction of the tumor [19, 20]. However, if the oxygen
supply to the treatment site is impaired too early, the treatment-
dependent hypoxia/ischemia will limit the photoreaction, ROS
production and cell killing [21]. Thus, premature destruction of
blood vessels is counterproductive for optimal photoreaction and
PDT response.
A metric for the cumulative photoreaction delivered at the
treatment site is the oxidative covalent crosslinking of the latent
transcription factor, Signal Transducer and Activator of Tran-
scription 3 (STAT3). The crosslinking of STAT3 is strictly pro-
portional to the delivered light dose and PS dose and thus can
be used as a molecular marker for the cumulative photoreaction
[22]. Quantification of vascular parameters before and during
PDT is desired for monitoring and optimizing the PDT response
that is manifested by the level of STAT3 crosslinking at the end of
light treatment.
There are several well-established techniques available for
quantification of blood flow such as dynamic-enhanced magnetic
resonance imaging (DCE-MRI) [23, 24] computed tomography
(CT) [25, 26] and positron emission tomography (PET) [27].
However, optical techniques are advantageous in that they allow
real-time monitoring without any contrast agent administration.
Among them, laser Doppler [10, 28–32] and optical coherence
tomography [33] have shown to be useful approaches with some
limitations for deep tissue applications. Recent work utilizing dif-
fuse correlation spectroscopy (DCS), which is an extension of the
dynamic light scattering technique for diffuse media, has proven
that DCS allows deeper penetration depth making it an attrac-
tive tool for monitoring PDT at preclinical and clinical settings
[17, 34–37].
In this study, we quantified blood flow dynamics with con-
tinuous measurements in a head and neck tumor model using
DCS. We investigated the relationship of blood flow dynamics as
a function of fluence rate and compared several empirical met-
rics derived from the blood flow dynamics with the crosslinking
of STAT3. We also investigated the status of endothelial cells
with CD31 staining after PDT. We show that blood flow dynam-
ics assessed by continuous DCS measurements can inform about
PDT-induced changes non-invasively, suggesting real-time blood
flow monitoring would allow for PDT optimization in clinical
settings.
Materials and Methods
Diffuse Correlation Spectroscopy
Blood flow was quantified by using previously described and val-
idated DCS technique [38, 39]. DCS measures rapid temporal
fluctuations of transmitted light through tissues and then uses
the autocorrelation functions associated with these fluctuations
to extract information about the motion of tissue scatterers, in
our case of red blood cells. Briefly, when photons scatter from
moving blood cells, they undergo phase shifts that make the
intensity of collected diffuse light fluctuate with time. The nor-
malized electric field, E (r, t), is extracted from the autocorrela-
tion function, g1 (r, τ ) = G1(r, τ )/<I >, where G1 (r, τ ) = <
E (r, t)E (r, t + τ) > is the electric field autocorrelation func-
tion, < I > is the time-averaged diffuse light intensity, r is the
source-detector separation and τ is the time delay. The informa-
tion about the motions in deep tissue can be extracted since the
electric field autocorrelation function satisfies a diffusion equa-
tion [38, 39]. The analytical solution of this diffusion equation
is available for the assumed nature of the particle motions of ran-
dom and Brownian diffusionmodel in reflectancemeasurements.
The mean-square displacement (< △r2 (τ ) >) of the red-blood
cells can be modeled as< △r2 (τ ) >= v2τ 2, for the random bal-
listic flow, and as < △r2 (τ ) >= 6DBτ, for the case of diffusive
motion; where v2 is the second moment of the cell velocity dis-
tribution and DB is the effective diffusion coefficient of the tissue
scatterers.
Empirically it has been observed in a broad range of studies
at preclinical and clinical settings that diffusion model fits the
autocorrelation curves better than random flow model and αDB
characterizes the blood flow in deep tissue [40–47]. Here α is a
factor representing the probability that a scattering event in tis-
sue is from a moving scatterer (α is generally proportional to
tissue blood volume fraction). We generally report relative blood
flow, rBF, to describe blood flow changes during PDT: rBF is
a blood flow parameter measured relative to its pre-treatment
value, i.e., rBF = αDB(t)/αDB(baseline).
The experimental aspect of DCS has been described elsewhere
[35, 36]. Briefly, it consisted of a high coherence length laser
(785 nm, CrystaLaser, Reno, NV), four photon-counting detec-
tors (Perkin Elmer, Waltham, MA) and a custom-built autocor-
relator board (Correlator.com). The source was directed to the
tissue by a multi-mode source fiber (400µm core, NA 0.22) and
collected with single-mode detector fibers (5µm core, NA 0.22).
The outputs from the photodetectors were sent to the correla-
tor board to determine the intensity autocorrelation function and
photon arrival times, which were then saved by the computer.
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For continuous measurements of the tumor vascular response
during PDT, the optical probe needed to be held off the surface
to prevent shading of the treatment light. To accomplish this,
a lightweight, non-contact probe (Figures 1A,B) was positioned
above the mouse [34, 48, 49]. This probe combined the deliv-
ery of the treatment light with the DCS fibers and is shown in
Figure 1A. A fiber-coupled collimator (ThorLabs, Newton, NJ)
was used to direct the light to the tissue. The detector fibers
were held in a custom assembly with a single 4mm diameter
lens, 4mm focal length (Edmund optics, Barrington, NJ). The
non-contact probe had adjustable arms for positioning the source
and detector spots on the tumor surface. One source and two
detectors were used for the non-contact probe, while the other
two detector channels were attached to the contact probe for
reading blood flow from the opposite hip for control and global
blood flow measurements. The source-detector separations for
the non-contact probe were 2.5 and 4mm, while the source-
detector separations for the contact probe were 0.6 and 1.6mm.
If we assumed the average light penetration depth ranges between
1/3 and 1/2 of the source-detector separations [37, 50], then the
average penetration depth in tumor would range approximately
from 0.83 to 2mm. The three legs of the tripod were attached to
a metal disc with a central hole creating a light treatment field of
approximately 1.1 cm in diameter (area= 1 cm2) (Figure 1C).
Mouse Model
All mouse studies were carried out in accordance with the
Roswell Park Cancer Institute Institutional Animal Care and Use
Committee. Female C3Hf/HeRos mice (n = 13) were acquired
from an in house breeding colony. At 12 weeks, mice were shaved
and inoculated subcutaneously on the right flank just above the
back leg with 3.5×105 SCCVII cells (a murine head and neck cell
line) suspended in 50µL phosphate buffered saline (PBS). Three
days later the skin over the tumor injection site and correspond-
ing site on the control leg was depilated with Nair and tumor
growth was monitored. After approximately 8 days the tumors
had reached∼ 7× 7mm.
To evaluate the histological effect of PDT in a human-relevant
head and neck tumor, a second mouse model was used for
tumor sectioning to assess the destruction of microvessels after
FIGURE 1 | Setup for continuous blood flow measurements during
PDT. (A) Schematic showing the basics of the DCS instrument including the
laptop, laser, correlator, and beam splitter along with the two probes in
relation to the mouse. The contact probe was placed directly on the mouse’s
hip while the non-contact probe was placed over the tumor. The solid red line
shows the DCS illumination light rays and the red dashed lines indicate DCS
detected light rays. (B) Schematic diagram and (C) picture of the probe
during PDT treatment of a mouse.
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PDT. Male SCID mice (n = 12) were acquired from an in
house-breeding colony and xenografts of a human hypopharyn-
geal cell line (FaDu) were grown at the same subcutaneous site
as described for the SCCVII. After approximately 14 days, the
tumors reached∼ 7× 7mm.
Non-invasive Measurements and PDT
A summary of the experimental timeline is shown in Figure 2.
Twenty-four hours before PDT, mice were injected i.v.
with 0.47µmol/kg of the photosensitizer Photoclor (2-[1-
Hexyloxyethyl]-2-devinylpyropheophorbide-a, HPPH). On the
day of the experiment, mice were placed on a heating pad to
maintain body temperature and anesthetized with isofluorane
during the treatment and measurement period. Temperature was
monitored every 5 min throughout treatment with a sub dermal
needle sensor digital thermometer. After 10 min for stabilization,
the non-contact DCS/treatment probe was positioned over the
tumor.
The tripod system was centered over the tumor so that only
the tumor and a small margin of normal tissue received the treat-
ment light. Marks on the metal disc showed where the source
and detector fibers were collimated for accurate probe position-
ing. The contact probe was contained in saran wrap and placed
in contact with the back left leg to measure blood flow changes at
a non-treatment site.
The treatment light with a wavelength of 665 nm was gen-
erated by an Argon pumped dye laser and was coupled to the
tripod with a 400µM fiber. The light was passed through a vari-
able attenuator to adjust the desired fluence rate. To prevent the
treatment light from interfering with the continuous DCS mea-
surements (785 nm), 665 nm light was filtered out by several lay-
ers of color filters (bluegrass, GAM color) placed in front of the
DCS detector fibers.
There were two treatment groups of mice, each receiving
different fluence rates: 14mW/cm2 (n = 5) and 75mW/cm2
(n = 5). The total delivered fluence was 100 J/cm2 for both
groups. Thus, the low fluence rate group (14mW/cm2) was
treated for approximately 119min and the high fluence rate
group (75mW/cm2) was treated for approximately 22min. To
obtain pre-PDT and post-PDT time-points, blood flow measure-
ments were acquired for 5min before treatment started and 5min
after treatment completed. There were three control mice: one
mouse received low fluence rate light with no photosensitizer, one
mouse received high fluence rate light with no photosensitizer
and one mouse received no light and no photosensitizer.
Blood Flow Related Parameters
To compare the blood flow dynamics between different mice
groups, the changes in relative blood flow (rBF) were plotted as a
function of delivered light dose. From the rBF plots, blood flow
variables were calculated for each mouse. All blood flow variables
are reported in the text as the average of all mice in the treat-
ment group ± standard deviation. Comparison between treat-
ment groups was performed using the Wilcoxon rank sum test
and significance was determined as p < 0.05.
Table 1 summarizes the investigated parameters in the blood
flow dynamics. The variables rBFmax and rBFmin are the val-
ues of rBF at the height of the first PDT induced blood flow
TABLE 1 | Summary of blood flow variables investigated from the
continuous blood flow dynamics.
Variable Description
-rBFmax (%) Max. rBF value of first PDT induced increase
-rBFmin(%) Min. value of rBF after first PDT induced increase
-JBFmax (J/cm2 ) Joules/cm2 delivered to rBFmax
-JBFmin (J/cm
2) Joules/cm2 delivered to rBFmin
-rBFfinal(%) rBF value at the end of treatment
-rBF50(%) 50% of baseline rBF
-J-50 (J/cm2) Joules/cm2 delivered to rBF50
-ILD (J/cm2 ) jBFmin – jBFmax
-FRR (J/cm2)−1 (rBFmax – rBFmin)/(jBFmin – jBFmax)
FIGURE 2 | Schematic of preclinical PDT highlighting the optical measurement times in relation to the HPPH injection and light delivery.
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FIGURE 3 | Representative plots of relative blood flow (rBF) dynamics as a function of delivered light fluence rates: (A) low fluence rate, (B) high
fluence rate. The blood flow metrics summarized in Table 1 are indicated on the plots.
increase and the base of that peak respectively. The J-BFmax and
J-BFmin are the fluence delivered to the maximum and minimum
rBF values of the first PDT induced peak. The J-50 is defined
as the energy delivered while the rBF remained above 50% of
baseline. This parameter is related to the delivered light when
blood flow is close to baseline levels or relatively high enough so
that tissue had enough available oxygenation that will effectively
contribute to the photoreaction. Similarly, the low blood flow
values would indicate oxygen depletion in tissue. The last two
variables in Table 1; the Interval Light Dose (ILD) and the Flow
Reduction Rate (FRR) are similar to previously reported param-
eters by Yu et al. [37]: the ILD indicates the light dose between
the first maximum blood flow and the first minimum blood flow
values, and the FRR indicates the slope between these max and
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TABLE 2 | Summary of the blood flow variables for each fluence rate group.
Fluence rate rBFmax (%) jBFmax (J/cm2) rBFmin (%) jBFmin (J/cm2) FRR (J/cm2)−1 ILD (J/cm2) J-50 (J/cm2) rBFfinal (%)
Low 119.9 [30.6] 9.2 [1.0] 38.1 [10.2] 25.2 [16.3] 13.7 [12.3] 16.1 [16.1] 22.8 [15.6] 16.9 [19.3]
High 120.0 [8.1] 1.5 [0.6]* 17.5 [9.8] 7.0 [3.4]* 22.0 [8.7] 5.5 [3.0] 8.4 [7.3] 76.5 [30.5]*
Values presented as mean [standard deviation].
* Indicates significance (p < 0.05).
FIGURE 4 | Cell killing by HPPH PDT. SCCVII cells were treated with 3 J/cm2 and the surviving cells after 24 post-PDT incubation are shown. (A) Shows 0 nM
HPPH, (B) 6.25 nM HPPH, and (C) 12.5 nM HPPH photosensitizer.
FIGURE 5 | STAT3 crosslinking is affected by both drug and light dose.
SCCVII cells were subjected to HPPH PDT under conditions as indicated at
the bottom. (A) Graphical representation of the relative level of STAT3
crosslinking as a function of HPPH concentration and delivered light fluence.
(B) Western blot images showing the PDT-dependent formation of STAT3
dimer complexes.
min values. All these variables are further illustrated in represen-
tative rBF plots during PDT for a mouse receiving low fluence
rate (Figure 3A) and high fluence rate (Figure 3B).
STAT3 Crosslinking
When cells containing a photosensitizer (HPPH in our case) are
treated with therapeutic light, the photoreaction causes the pro-
duction of singlet oxygen and other ROS which oxidize a broad
range of molecules. Figure 4A shows the SCCVII cells surviving
24 h post PDT (3 J/cm2) with no administered photosensitizer
(control) while Figures 4B,C show cells treated with 6.25 nM
and 12.5 nM HPPH, respectively. One immediate and preferen-
tial target of singlet oxygen/ROS is latent STAT3 that is cova-
lently crosslinked to homodimers [51]. Figure 5A (the graph-
ical representation of the Western blots in Figure 5B) shows
the STAT3 crosslinking is affected by both HPPH concentration
and light dose in SCCVII cells. The level of STAT3 crosslink-
ing in tumor tissue subjected to PDT in situ was determined
by excising the tumor immediately following light treatment,
mincing tumor tissue and extracting proteins by sonication in
RIPA buffer. Aliquots of cleared extracts, containing 20µg pro-
teins, were separated under denatured condition on 6% SDS
polyacrylamide gels and analyzed by immunoblotting for the
level of homodimeric STAT3 relative to total STAT3 as reported
previously [22, 52].
Microvessel Density Staining
To visualize the impact of fluence rate on tumor vascula-
ture, FaDu xenografts were used. SCID mice with subcutaneous
human FaDu tumor were given the same PDT treatment regi-
mens as mentioned above for the SCCVII tumors: low fluence
rate PDT (n = 5), high fluence rate PDT (n = 5) and no-
light controls (n = 2). After PDT, the tumors were removed and
embedded in Optimal Cutting Temperature (OCT) compound
and 5µm-thick sections cut in a cryostat. Tumor sections were
fixed in 4% paraformaldehyde and processed for immunohisto-
chemical staining of the endothelial cell marker CD31. To calcu-
late microvessel density after PDT, three regions of 1000 × 1000
pixels were selected from each tumor. A customMatlab program
determined the percentage of the image stained for CD31. Treat-
ment groups were compared using the Wilcoxon rank sum test
to assess significance (p < 0.05). Microvessel density here is
reported as the percentage of the image stained for the vascular
marker [53].
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FIGURE 6 | Relative blood flow (rBF) dynamics indicate the
differences for the two treatment groups. (A) Tumor rBF for mice
treated with high fluence rate and (B) Tumor rBF for mice treated with
the low fluence rate. (C) Hip muscle rBF for mice treated with high
fluence rate. (D) Hip muscle rBF for mice treated with low fluence rate.
(E) Tumor rBF for control mice treated with high fluence rate. (F) Tumor
rBF for control mice treated with low fluence rate. (G) Tumor rBF for
control mice with no treatment light.
Results and Discussion
Head and neck tumors in mice treated with HPPH-PDT showed
several characteristic features of blood flow dynamics during
light exposure. Once the treatment light was applied, there was
typically an increase in blood flow followed by a decrease. As
shown in Figure 6A blood flow in tumors treated with high flu-
ence rate undergo a drastic reduction that progressively recovers
over the remaining treatment period, resulting in rBFfinal val-
ues close to the pre-treatment values. In contrast, the blood flow
in tumors treated with low fluence rate showed a continuous
decrease throughout treatment (Figure 6B).
More specifically, the magnitude of the initial increase
(rBFmax) was similar for both groups (119.9 ± 30.6% vs. 120.0 ±
8.1% for the low fluence rate and high fluence rate, respectively).
For the high fluence rate group, the initial increase occurred very
early in the treatment (J-BFmax = 1.5 ± 0.6 J/cm
2) and was
followed almost immediately by a rapid decrease. For the low flu-
ence rate group, the initial increase in blood flow occurred much
later (J-BFmax = 9.2 ± 1.0 J/cm
2) and the decrease was not as
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FIGURE 7 | CD31 microvessel staining post-PDT. (A) CD31 staining from a high-fluence-rate treated mouse (B) low-fluence-rate treated mouse (C) control
mouse. The black arrows highlight regions of staining. (D) Quantitative bar plot representation of the CD31 microvessel staining for each group.
FIGURE 8 | STAT3 crosslinking showed a substantial difference
between the high- and low-fluence-rate groups.
rapid as the high fluence rate case. The difference in J-BFmax
for the two fluence rate groups was significantly different (p =
0.016). The rBFfinal between the two fluence rate groups was also
significant (76.5 ± 30.5% for the high-fluence-rate and 16.9±
19.3% for the low-fluence-rate group, p = 0.032). A summary
of blood flow parameters investigated is shown in Table 2.
These results may imply that that HPPH-PDT with high-
fluence-rate induced acute blood flow shutdown early in the
treatment with no permanent destruction of vasculature, result-
ing in a delayed low, but measurable recovery of blood flow
accounting for an overall ineffective PDT. Figures 6C,D show the
rBF during PDT measured on the contra-lateral hip, away from
the treatment light. Neither the high fluence rate treated mice
(Figure 6C) nor the low fluence rate treated mice (Figure 6D)
showed a PDT induced reduction in blood flow. These results
indicate that PDT induced vascular effects mainly in the tumor
and these changes were not due to systemic effects.
To further verify that these vascular changes were indeed
induced by PDT, control mice with no administered photosen-
sitizer were also measured. Figures 6E–G show the data for the
control group that did not receive photosensitizer. Figures 6E,F
show the groups that had high fluence rate and low-fluence rate
light, respectively, while Figure 6G shows the control group with
no administered light. For all three groups there was no measur-
able decrease of blood flow and in fact the two light-administered
control group showed increases in rBF during illumination, prob-
ably due to local heating. The control group with no drug or light
showed stable rBF over 30min. Thus, we can infer that the vascu-
lar shutdown observed in Figures 6A,B were mainly due to PDT.
As shown in Figure 7, the high fluence rate group (Figure 7A)
and control group (Figure 7C) had visible staining for blood ves-
sels (arrows), indicating there were significant number of vessels
present after PDT for both groups. On the other hand, the low-
fluence-rate group did show less staining of vessels (Figure 7B).
The microscopic data confirmed our macroscopic observations
of vascular impairment caused by the PDT treatment. The quan-
titation of the CD31-postive cells indicated that at post-PDT
the control and the high-fluence-rate group had an average
microvessel density of 3.91 ± 1.60% and 3.97 ± 2.25%, respec-
tively (Figure 7D), and these values were not statistically different
(p > 0.05, Wilcoxon rank sum test). In contrast, the low-fluence-
rate group had an average of 1.22 ± 1.10% percent staining and
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FIGURE 9 | STAT3 crosslinking as a function of various blood flow metrics for the C3H mice with SCCVII tumors. (A) Flow reduction rate, (B) interval light
dose, and (C) the new metric J-50.
FIGURE 10 | The fluence rate of therapeutic light affects the tumor vasculature and can lead to effective or ineffective PDT.
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was significantly lower than both the high-fluence-rate (p = 1.4e-
5) and control (p = 0.0006) groups. These results highlight that
compared to high-fluence-rate PDT, low-fluence-rate PDT did
result in a more effective destruction of tumor vasculature.
Next, we compared our non-invasive blood flow measure-
ments with the delivered photoreaction within the tumor as
determined by the level of STAT3 dimerization immediately
following light treatment. Since STAT3 crosslinking is directly
proportional to the photosensitizer-mediated photoreaction, it
serves as a molecular marker of deposited PDT dose. As shown in
Figure 8, STAT3 crosslinking was 17.8 ± 10.9% (average ± stan-
dard deviation) for the low-fluence-rate group and 7.0± 6.3% for
the high-fluence-rate group.
Then, the blood flow metrics discussed above were compared
to the STAT3 crosslinking to determine whether any of the opti-
cal metrics could provide a non-invasive tool to infer about the
photoreaction. We observed that, as summarized in Figure 9,
blood FRR and ILD metrics correlated reasonably well with the
STAT3 crosslinking (r2 = 0.745 and r2 = 0.795, respectively). As
Figure 9A indicates, if the blood flow decreases too rapidly, there
would be less available oxygen (and drug) in tissue, which would
lead to less PDT photoreaction and less STAT3 crosslinking.
Additionally, the light-dose interval (Figure 9B) and the joules
delivered while the blood flow was above 50% (J-50) (Figure 9C)
correlated well with STAT3 crosslinking (r2 = 0.7953 and
0.872). These results indicate that blood flow dynamics, measured
with DCS, can non-invasively assess the PDT photoreaction and
destruction of microvasculature.
Blood flow controls the delivery of nutrients and oxygen to
tumors. Targeting vasculature is a common mechanism of action
for many cancer therapies, including PDT. Therefore, it is impor-
tant to measure the blood flow of tumors before, during and
after PDT. The blood flow dynamics can indicate PDT effects in
real-time and possibly predict the response, which for patients is
typically assessed 3 months after PDT. Immediate assessment is
of particular interest to allow for earlier re-treatment if necessary.
Noninvasively measured metrics and STAT3 crosslinking may be
biomarkers of the PDT response. In this study, we focused on sev-
eral metrics related to the blood flow dynamics such as the final
value of the blood flow at the completion of the treatment, the
blood FRR, the light dose interval when the blood flow reached
the highest and lowest values, and the delivered light dose while
the blood flow values were effectively high during the treatment.
These parameters indicated substantial differences with respect
to the administered PDT treatment light fluence rates, which
were confirmed with the CD31 staining and STAT3 crosslinking
studies [54–57].
Figure 10 proposes the mechanistic basis for the different out-
comes of low and high fluence rate PDT. During effective PDT as
achieved by low fluence, blood vessels in the tumor remain open
early in the treatment. This allows oxygen to be resupplied while
it is continuously being consumed during PDT. As the treatment
progresses, blood vessels begin to shut down, limiting the amount
of available oxygen for PDT. After treatment the majority of
blood vessels are expected to stay shutdown, preventing oxygen
and nutrients from the tumor (indirect tumor killing). During
low-fluence-rate PDT, since both oxygen and PS were avail-
able throughout the treatment, sufficient photoreaction occurs to
destroy the tumor. During high-fluence-rate PDT, blood vessels
are shutdown very early in the treatment, limiting the available
oxygen. The blood vessels recover later in the treatment, but
there is no longer sufficient PS in the tumor for effective PDT.
The treatment ends with little photoreaction occurring due to the
rapid deprivation of oxygen early in the treatment.
Our results show that vascular shutdown mainly occurred
when both drug and light were administered. The contralateral
hip measurements did not indicate any major reduction of blood
flow, but did show some fluctuations that may be the conse-
quence of local and systemic effects caused by PDT. The mice
treated with only light also did not show vascular shutdown.
The high fluence rate treated control mouse showed a steady
increase in blood flow during light administration, possibly due
to vasodilation caused by heating of the skin.
There was no statistical difference in post-PDT microvessel
density between the high-fluence-rate and control groups. Mice
treated with low-fluence-rate PDT showed statistically lower
post-PDT microvessel density than the control and high fluence
rate groups. This indicates that low fluence-rate-PDT led to
a more complete vascular shutdown, while high fluence rate
PDT led to an early temporary reduction of blood flow followed
by a partial or possibly a complete recovery. This has major
implications for long-term recovery since vascular shutdown
is often a goal of PDT to prevent nutrients and oxygen from
reaching the tumor. For technical reasons, the microvessel
density could only be determined for post-PDT tumor tissue
because removing a portion of the tumor before PDT would
cause bleeding, interfering with the blood flow measurements.
As previously already demonstrated, an accurate measure for
vasculature shutdown is the change in microvessel density
[10, 17, 19, 54–62].
Conclusion
Our results indicate that high and low fluence rates induce char-
acteristically different blood flow dynamics. The vascular effects
were also visible from the CD31-positive vessel staining of the
tumor sections, confirming the dependency on the fluence rate.
In addition, the metrics derived from the blood flow dynam-
ics correlated with the STAT3 crosslinking. Higher crosslinking
was observed for tumors treated with the low fluence rate than
those treated with the high fluence rate indicating an overall
greater photoreaction. The primary advantage of opticalce mea-
surements of blood flow dynamics is the assessment of PDT effi-
cacy in near real-time. The parameters could provide feedback
to the physician, allowing adjustment of the treatment light in
the event of excessively rapid vascular shutdown. Since oxygen
and photosensitizer are crucial for PDT, assessing tissue oxy-
gen saturation and photosensitizer content would provide addi-
tional indicators about the ongoing PDT photoreaction. Imple-
menting concurrent measurements of blood flow, oxygen, and
photosensitizer content would be a next step.
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